$CRLBF

Cresco Labs Inc. (CSE: CL, OTCQX: CRLBF, FSE: 6CQ) appointed Edward Tilly, former CBOE Chairman and CEO, to its Board of Directors. Tilly brings over 35 years of experience in exchange operations and capital markets. He will serve as an independent director and join the Audit Committee, effective September 18, 2026. Tilly's expertise is expected to aid Cresco Labs as it navigates U.S. capital markets and legislative changes.

Cresco Labs (CRLBF) shares rose 10% in a month, driven by strong Q2 2026 results. Revenue increased 15% to $173M, with improved margins. Management expects Q3 revenue to be stable but margins to normalize. The company faces competition from peers like Verano (VRNO) and Curaleaf (CURLF). Analysts have mixed loss-per-share estimates for 2026 and 2027.

Simply Wall St reports Cresco Labs’ Q2 results shifted to profitability, with revenue of US$173.3m (vs. US$166.1m), net income of US$16.8m (vs. a US$16.3m loss), and basic EPS of US$0.045. Adjusted EBITDA was US$40m, with a 22.8% margin and 51.6% adjusted gross margin. Operating cash flow was US$15m vs capex US$9m, while management guided Q3 EBITDA margin near 20%.

Cresco Labs Inc. (OTCMKTS:CRLBF) shares rose 3.6% to $0.9498 after trading as high as $0.98 on Monday; the article says 476,660 shares changed hands, down 31% from average volume. Zacks upgraded the stock from “strong sell” to “hold.” For the quarter ended May 8, EPS was -$0.04 vs -$0.03 estimate on revenue of $151.33M vs $148.58M.

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -33.33% and 0.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Curaleaf Holdings CURLF shares closed up 19.72% at $1.08 Cresco Labs CRLBF shares closed up 15.52% at $0.97 FLUENT CNTMF shares closed up 15.38% at $0.06 Global Hemp Group GBHPF shares closed up 14.45% at $0.01 Urban-gro UGRO shares closed up 14.27% at $0.45